Another randomized phase III ExteNET trial of 2840 HER2+/HR+ early-stage breast cancer patients compared 1 year of adjuvant daily neratinib with placebo after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab [25]. This evidence concerns the gene ERBB2 and breast cancer.